A Phase 4 interventional study of boceprevir and peginterferon alfa-2a [Pegasys] in Hepatitis C, Chronic, sponsored by Hoffmann-La Roche. Completed at 32 sites in 6 countries. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2016-11-02.
Sponsored by Hoffmann-La Roche · Phase 4, Interventional, and Treatment
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 83 studies testing peginterferon alfa-2a in Hepatitis C, Chronic — none open to participants now, none under way, none of them phase 3. peginterferon alfa-2a · Hepatitis C, Chronic.
Among the 83 studies testing peginterferon alfa-2a in Hepatitis C, Chronic, this one is the 35th largest by enrollment, is one of 7 that started in 2012, is one of 48 in phase 4, and was the 70th registered.
950 studies on the registry are indexed under Hepatitis C, Chronic; 8 are open to participants now.
Browse Hepatitis C, Chronic studies →None of the 83 studies testing peginterferon alfa-2a in Hepatitis C, Chronic is open now. The open studies under Hepatitis C, Chronic, anywhere →
peginterferon alfa-2a: first FDA approval 2002 (PEGASYS), first EMA approval 2002. What it is approved for, and how studies give it, is on its page →
Of the 5 Hepatitis C, Chronic studies recruiting now, 2 set no upper age limit and 2 stop at 75 or younger; 1 takes children under 18; 1 takes healthy volunteers.
This study: 18 Years and older · all sexes · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
83 studies; the count open now beside each. This study's row is marked.
A study in two phases is counted once above. Listed by phase, each with its combined phases: Phase 1 3 · Phase 2 12 · Phase 3 20 · Phase 4 48
First in 2000; this study’s year is marked. 7 started in 2012.
By drug class, each counting the studies that test any of its medicines:
This study's enrollment of 165 is above the median of 90 across 696 interventional studies indexed under Hepatitis C, Chronic.
Median enrollment 129 across the 83 interventional studies. Of the 75 that completed or were terminated, 38 (51%) have results posted.
This tab as a report to print or save as PDF → With an account.
44 of 83 have an industry lead sponsor. The 10 most frequent:
Hoffmann-La Roche is the lead sponsor of 2,102 studies on the registry; 89 are open to participants now.
Of its 330 completed or terminated interventional studies of FDA-regulated products, 248 (75%) have results posted.
86 studies in Hepatitis C, Chronic by Hoffmann-La Roche: none open now, none under way, none of them phase 3. Of 84 finished, 48 (57%) have results posted.
Among the 86 studies in Hepatitis C, Chronic by Hoffmann-La Roche, this one is the 30th largest by enrollment of the 59 interventional ones that give a count, is one of 10 that started in 2012, is one of 29 in phase 4, and was the 60th registered.
Hoffmann-La Roche’s Hepatitis C, Chronic studies by the year they started, since 2001.
None of the studies under way reaches primary completion within a year.
Among the 83 studies testing peginterferon alfa-2a in Hepatitis C, Chronic, from their registry updates:
Nothing recorded among them since 2026-09-25.
Among Hoffmann-La Roche’s 86 in Hepatitis C, Chronic:
Nothing recorded among them since 2026-09-25.
This tab as a report to print or save as PDF → With an account.
This open-label, multicenter, treatment response guided study will evaluate the sustained virological response and safety of the triple combination therapy boceprevir, Pegasys (peginterferon alfa-2a) and Copegus (Ribavirin) in previously untreated patients with genotype 1 chronic hepatitis C. In the lead-in phase, patients will receive a dual combination therapy of Pegasys and Copegus for 4 weeks. In the following triple combination therapy phase, 800 mg boceprevir, 180 mcg Pegasys and 1000-1200 mg Copegus will be administered for 24, 32 or 44 weeks; the duration depending on the patient's treatment response. The anticipated time on study treatment is up to 48 weeks.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Hepatitis C is a virus that infects the liver. An HCV antibody test can stay positive after an infection has cleared (and is occasionally positive without one); an HCV RNA test shows whether the virus is there now.
After treatment, hepatitis C counts as cured when HCV RNA is still undetectable 12 weeks or more after the treatment ended. Studies often accept people cured this way.
A score of how well the liver works in people with liver disease such as cirrhosis: class A is mild, B moderate and C severe.
Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).
Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.
A drug or device being studied in a clinical trial.
It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.
Hepatitis B is a virus that infects the liver. These are separate tests: HBsAg positive usually means a current infection (a recent vaccination can briefly cause it too); total anti-HBc (HBcAb) positive means an infection now or in the past; HBV DNA measures how much virus is in the blood.
Some studies accept a past infection if HBV DNA is undetectable, sometimes with antiviral medicine during the study. Check what this study allows.
The human immunodeficiency virus, which weakens the immune system.
Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.
Hepatitis C tests
Hepatitis C is a virus that infects the liver. An HCV antibody test can stay positive after an infection has cleared (and is occasionally positive without one); an HCV RNA test shows whether the virus is there now.
After treatment, hepatitis C counts as cured when HCV RNA is still undetectable 12 weeks or more after the treatment ended. Studies often accept people cured this way.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Child-Pugh class
A score of how well the liver works in people with liver disease such as cirrhosis: class A is mild, B moderate and C severe.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Childbearing potential
Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).
Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Investigational drug or device
A drug or device being studied in a clinical trial.
It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Hepatitis B tests
Hepatitis B is a virus that infects the liver. These are separate tests: HBsAg positive usually means a current infection (a recent vaccination can briefly cause it too); total anti-HBc (HBcAb) positive means an infection now or in the past; HBV DNA measures how much virus is in the blood.
Some studies accept a past infection if HBV DNA is undetectable, sometimes with antiviral medicine during the study. Check what this study allows.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
HIV
The human immunodeficiency virus, which weakens the immune system.
Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Drug: peginterferon alfa-2a [Pegasys] · Drug: ribavirin (Copegus]
Drug: boceprevir · Drug: peginterferon alfa-2a [Pegasys] · Drug: ribavirin (Copegus]
800 mg three times daily for 24, 32 or 44 weeks
180 mcg subcutaneously once a week for 24, 32 or 44 weeks
180 mcg subcutaneously once a week for 4 weeks
1000 mg or 1200 mg orally once a day for 24, 32 or 44 weeks
1000 mg or 1200 mg orally once a day for 4 weeks
Percentage of Participants With Sustained Virological Response (SVR) at 12 Weeks After End of Treatment (EOT)
SVR at 12 weeks after EOT was defined as an undetectable HCV RNA viral load obtained 12 weeks following completion of treatment. HCV RNA viral load was measured using the Roche COBAS TaqMan 2.0 HCV Test, with a lower limit of detection (LOD) of 10 to 15 international units per milliliter (IU/mL). The percentage of participants with SVR was calculated as \[number of participants with undetectable HCV RNA at 12 weeks after EOT divided by the number of participants analyzed\] multiplied by 100.
Time frame: At 12 weeks after EOT (up to 60 weeks)
Percentage of Participants With SVR at 24 Weeks After EOT
SVR at 24 weeks after EOT was defined as an undetectable HCV RNA viral load obtained 24 weeks following completion of treatment. HCV RNA viral load was measured using the Roche COBAS TaqMan 2.0 HCV Test, with a lower LOD of 10 to 15 IU/mL. The percentage of participants with SVR was calculated as \[number of participants with undetectable HCV RNA at 24 weeks after EOT divided by the number of participants analyzed\] multiplied by 100.
Time frame: At 24 weeks after EOT (up to 72 weeks)
HCV RNA Levels
HCV RNA levels were obtained routinely during and after treatment. Mean HCV RNA levels were calculated by averaging the HCV RNA levels among all participants analyzed at each collection timepoint and expressed in log10 IU/mL.
Time frame: At Baseline; Weeks 2, 4, 6, 8, 12, 16, 24, 28, and 36; EOT; and 12 and 24 weeks after EOT (up to 72 weeks)
Percentage of Participants With Virological Response
HCV RNA levels were obtained routinely during and after treatment. The percentage of participants with undetectable HCV RNA viral load (ie, virological response) was calculated as \[number of participants with undetectable HCV RNA at each timepoint divided by the number of participants analyzed\] multiplied by 100.
Time frame: At Weeks 2, 4, 6, 8, 12, 16, 24, 28, and 36; and EOT (up to 48 weeks)
Percentage of Participants With at Least a 1-Log, 2-Log, or 3-Log Reduction in HCV RNA
HCV RNA levels were obtained routinely during and after treatment. Reductions in HCV RNA viral load by 1-log, 2-log, or 3-log increments were determined relative to Baseline HCV RNA. Each increment represents a reduction greater than or equal to (≥) the specified log value, including results for which HCV RNA was below the limit of quantification (25 IU/mL). The percentage of participants with each log reduction in HCV RNA was calculated as \[number of participants with log reduction divided by the number of participants analyzed\] multiplied by 100.
Time frame: At Weeks 2, 4, 6, 8, 12, 16, 24, and 28
Percentage of Participants With Virological Relapse Following EOT Response
Virological relapse was defined as a detectable post-treatment HCV RNA viral load following a previously undetectable EOT level (ie, virological response). The percentage of participants with virological relapse was calculated as \[number of participants meeting the above criteria divided by the number of participants analyzed\] multiplied by 100.
Time frame: Up to 72 weeks (at 12 and 24 weeks after EOT)
Percentage of Participants With Virological Breakthrough Following On-Treatment Response
Virological breakthrough was defined as an HCV RNA viral load greater than (\>) 1000 IU/mL following a previously undetectable level at any time during treatment (ie, virological response). Participants who ultimately achieved an EOT response were not considered for virological breakthrough. The percentage of participants with virological breakthrough was calculated as \[number of participants meeting the above criteria divided by the number of participants analyzed\] multiplied by 100.
Time frame: Up to 48 weeks (at Baseline; Weeks 2, 4, 6, 8, 12, 16, 24, 28, and 36; and EOT)
Percentage of Participants With Virological Rebound Following On-Treatment Decline in HCV RNA
Virological rebound was defined as an HCV RNA viral load \>1000 IU/mL and a ≥1-log increase from nadir following a decline in HCV RNA from Baseline at any time during treatment (ie, on-treatment decline). Participants who ultimately achieved an EOT response were not considered for virological rebound. The percentage of participants with virological rebound was calculated as \[number of participants meeting the above criteria divided by the number of participants analyzed\] multiplied by 100.
Time frame: Up to 48 weeks (at Baseline; Weeks 2, 4, 6, 8, 12, 16, 24, 28, and 36; and EOT)
Percentage of Participants With Treatment Discontinued Based Upon Elevated (Week 12) or Detectable (Week 24) HCV RNA
Treatment was to be discontinued for participants who met prespecified criteria, termed the futility rule, after 12 or 24 weeks of treatment. Participants were discontinued from treatment for one of the following reasons: HCV RNA viral load ≥100 IU/mL (Week 12) or a detectable HCV RNA viral load (Week 24). HCV RNA viral load was measured using the Roche COBAS TaqMan 2.0 HCV Test, with a lower LOD of 10 to 15 IU/mL. The percentage of participants with treatment discontinued for each reason was calculated as \[number of participants meeting one of the above criteria divided by the number of participants analyzed\] multiplied by 100.
Time frame: At 12 and 24 weeks
Duration of Treatment With PEG-IFN, RBV, and Boceprevir
The duration of treatment with each study drug was determined as the time from treatment start until the last dose of PEG-IFN, RBV, or boceprevir. Median duration of treatment was determined using the actual duration of treatment among individual participants and expressed in weeks.
Time frame: Up to 48 weeks (from Baseline until EOT)
Percentage of Participants With a Dose Modification of PEG-IFN, RBV, or Boceprevir By Reason
Dose modifications for each study drug included any dose reduction, treatment interruption, or premature withdrawal. Adverse event (AE)-related reasons were documented, as well as reasons related to insufficient efficacy ('Poor efficacy') or other safety-related reasons ('Safety/other'). The percentage of participants with a dose modification documented for each reason was calculated as \[number of participants with dose modification divided by the number of participants analyzed\] multiplied by 100.
Time frame: Up to 48 weeks (from Baseline until EOT)
Percentage of Participants Receiving Target Administrations of PEG-IFN, RBV, and Boceprevir
The frequency of missed treatments was examined using the number of administrations received as a percentage of target administrations for each study drug. The maximum number of possible administrations was considered in terms of once-weekly injections with PEG-IFN and in terms of treatment days with RBV and boceprevir. The percentage of target administrations each participant received was separated into ranges of \<60%, 60 to \<80%, 80 to \<95%, and ≥95% for each study drug. The percentage of participants who received each range of target administrations was calculated as \[number of participants in each range divided by the number of participants analyzed\] multiplied by 100.
Time frame: Up to 48 weeks (from Baseline until EOT)
Number of Participants With a Safety-Related Dose Modification
Dose modifications for each study drug included any dose reduction, treatment interruption, or premature withdrawal. The percentage of participants with a safety-related dose modification (eg, modification due to adverse event or laboratory abnormality) of any study drug was calculated as \[number of participants with dose modification divided by the number of participants analyzed\] multiplied by 100.
Time frame: Up to 48 weeks (from Baseline until EOT)
Time to Safety-Related Dose Modification
Dose modifications for each study drug included any dose reduction, treatment interruption, or premature withdrawal. Median time to safety-related dose modification (eg, modification due to adverse event or laboratory abnormality) of any study drug was estimated using Kaplan-Meier and expressed in weeks.
Time frame: Up to 48 weeks (from Baseline until EOT)
Percentage of Participants Using Concomitant Hematopoietic Stimulants During Treatment and Follow-Up
Use of concomitant hematopoietic stimulants (such as epoetin) during the 48-week treatment period and/or within 24 weeks of follow-up was documented. The percentage of participants using concomitant hematopoietic stimulants was calculated as \[number of participants reporting concomitant use divided by the number of participants analyzed\] multiplied by 100.
Time frame: Up to 72 weeks (from Baseline until 24 weeks after EOT)
Percentage of Participants With a Concomitant Disease Prior to or During the Study
The prevalence of concomitant disease at any time from Screening through the end of follow-up was documented. The percentage of participants with a concomitant disease was calculated as \[number of participants reporting or diagnosed with concomitant disease divided by the number of participants analyzed\] multiplied by 100. Diseases documented for ≥5% of participants included hypertension, diabetes mellitus, hypothyroidism, and vitamin D deficiency as reported here.
Time frame: Up to 76 weeks (from Screening until 24 weeks after EOT)
Percentage of Participants Using Concomitant Medications During Treatment and Follow-Up
Use of concomitant prescription or nonprescription medications during the 48-week treatment period and/or within 24 weeks of follow-up was documented. The percentage of participants using concomitant medications was calculated as \[number of participants reporting concomitant use divided by the number of participants analyzed\] multiplied by 100. Medication classes reported by \>10% of participants included analgesics, nonsteroidal anti-inflammatory drugs (NSAIDs), antihistamines, corticosteroids, proton pump inhibitors, vitamins and minerals, and beta-adrenoceptor blocking agents as reported here.
Time frame: Up to 72 weeks (from Baseline until 24 weeks after EOT)
| Milestone | Total Population |
|---|---|
| Started | 165 |
| Completed | 139 |
| Not completed | 26 |
| Withdrew: Adverse event or intercurrent illness | 5 |
| Withdrew: Futility rule (week 12) | 7 |
| Withdrew: Futility rule (week 24) | 3 |
| Withdrew: Rebound or breakthrough | 3 |
| Withdrew: Treatment discontinued by error | 1 |
| Withdrew: Lost to follow-up | 1 |
| Withdrew: Noncompliance | 1 |
| Withdrew: Participant refusal | 3 |
| Withdrew: Withdrawal by subject | 1 |
| Withdrew: Protocol violation | 1 |
SVR at 12 weeks after EOT was defined as an undetectable HCV RNA viral load obtained 12 weeks following completion of treatment. HCV RNA viral load was measured using the Roche COBAS TaqMan 2.0 HCV Test, with a lower limit of detection (LOD) of 10 to 15 international units per milliliter (IU/mL). The percentage of participants with SVR was calculated as \[number of participants with undetectable HCV RNA at 12 weeks after EOT divided by the number of participants analyzed\] multiplied by 100.
| percentage of participants | Total Population | Cirrhotics | Poor Responders | Late Responders | Early Responders | Others |
|---|---|---|---|---|---|---|
| Percentage of Participants With Sustained Virological Response (SVR) at 12 Weeks After End of Treatment (EOT) | 81 (74 to 86) | 70 (46 to 88) | 75 (53 to 90) | 88 (68 to 97) | 95 (87 to 99) | 32 (13 to 57) |
SVR at 24 weeks after EOT was defined as an undetectable HCV RNA viral load obtained 24 weeks following completion of treatment. HCV RNA viral load was measured using the Roche COBAS TaqMan 2.0 HCV Test, with a lower LOD of 10 to 15 IU/mL. The percentage of participants with SVR was calculated as \[number of participants with undetectable HCV RNA at 24 weeks after EOT divided by the number of participants analyzed\] multiplied by 100.
| percentage of participants | Total Population | Cirrhotics | Poor Responders | Late Responders | Early Responders | Others |
|---|---|---|---|---|---|---|
| Percentage of Participants With SVR at 24 Weeks After EOT | 80 (73 to 86) | 70 (46 to 88) | 71 (49 to 87) | 88 (68 to 97) | 95 (87 to 99) | 32 (13 to 57) |
HCV RNA levels were obtained routinely during and after treatment. Mean HCV RNA levels were calculated by averaging the HCV RNA levels among all participants analyzed at each collection timepoint and expressed in log10 IU/mL.
| log10 IU/mL | Total Population | Cirrhotics | Poor Responders | Late Responders | Early Responders | Others |
|---|---|---|---|---|---|---|
| Baseline (n=165,20,24,24,78,19) | 6.29 ± 0.722 | 6.34 ± 0.710 | 6.40 ± 0.592 | 6.46 ± 0.530 | 6.18 ± 0.796 | 6.34 ± 0.762 |
| Week 2 (n=159,18,24,23,76,18) | 4.86 ± 1.418 | 5.06 ± 1.288 | 6.07 ± 0.610 | 5.38 ± 0.767 | 4.27 ± 1.441 | 4.90 ± 1.597 |
| Week 4 (n=158,20,24,22,75,17) | 4.06 ± 1.525 | 4.30 ± 1.533 | 5.78 ± 0.550 | 4.60 ± 0.874 | 3.25 ± 1.289 | 4.24 ± 1.689 |
| Week 6 (n=151,18,24,21,73,15) | 1.75 ± 0.882 | 2.01 ± 1.002 | 2.70 ± 0.972 | 1.91 ± 0.570 | 1.25 ± 0.154 | 2.18 ± 1.337 |
| Week 8 (n=160,20,24,24,77,15) | 1.47 ± 0.638 | 1.69 ± 0.650 | 1.95 ± 0.874 | 1.52 ± 0.329 | 1.18 ± 0.000 | 1.84 ± 1.236 |
| Week 12 (n=160,20,24,24,77,15) | 1.35 ± 0.682 | 1.41 ± 0.393 | 1.69 ± 1.316 | 1.25 ± 0.107 | 1.18 ± 0.000 | 1.74 ± 1.292 |
| Week 16 (n=156,19,22,24,78,13) | 1.25 ± 0.405 | 1.34 ± 0.459 | 1.46 ± 0.906 | 1.19 ± 0.045 | 1.18 ± 0.000 | 1.32 ± 0.458 |
| Week 24 (n=152,17,23,24,78,10) | 1.41 ± 1.042 | 1.80 ± 1.753 | 1.83 ± 1.696 | 1.18 ± 0.000 | 1.18 ± 0.000 | 2.21 ± 1.916 |
| Week 28 (n=143,15,19,23,76,10) | 1.23 ± 0.480 | 1.18 ± 0.000 | 1.45 ± 1.173 | 1.18 ± 0.000 | 1.18 ± 0.025 | 1.48 ± 0.822 |
| Week 36 (n=71,16,21,24,3,7) | 1.69 ± 1.563 | 1.54 ± 1.412 | 2.00 ± 2.069 | 1.33 ± 0.745 | 2.60 ± 2.466 | 1.91 ± 1.930 |
| EOT (n=162,20,24,23,78,17) | 1.52 ± 1.120 | 1.58 ± 1.167 | 1.87 ± 1.563 | 1.38 ± 0.996 | 1.18 ± 0.025 | 2.73 ± 1.943 |
| 12 weeks after EOT (n=152,19,24,23,74,12) | 1.92 ± 1.792 | 2.53 ± 2.340 | 2.48 ± 2.345 | 1.48 ± 1.087 | 1.40 ± 0.946 | 3.83 ± 2.789 |
| 24 weeks after EOT (n=159,20,23,24,78,14) | 2.00 ± 1.874 | 2.66 ± 2.351 | 2.39 ± 2.327 | 1.77 ± 1.605 | 1.42 ± 1.053 | 4.05 ± 2.592 |
HCV RNA levels were obtained routinely during and after treatment. The percentage of participants with undetectable HCV RNA viral load (ie, virological response) was calculated as \[number of participants with undetectable HCV RNA at each timepoint divided by the number of participants analyzed\] multiplied by 100.
| percentage of participants | Total Population | Cirrhotics | Poor Responders | Late Responders | Early Responders | Others |
|---|---|---|---|---|---|---|
| Week 2 | 4 (1 to 8) | 0 (0 to 17) | 0 (0 to 14) | 0 (0 to 14) | 6 (2 to 14) | 5 (0 to 26) |
| Week 4 | 7 (4 to 12) | 0 (0 to 17) | 0 (0 to 14) | 0 (0 to 14) | 14 (7 to 24) | 5 (0 to 26) |
| Week 6 | 41 (34 to 49) | 35 (15 to 59) | 0 (0 to 14) | 4 (0 to 21) | 71 (59 to 80) | 26 (9 to 51) |
| Week 8 | 61 (53 to 68) | 45 (23 to 68) | 13 (3 to 32) | 0 (0 to 14) | 100 (95 to 100) | 53 (29 to 76) |
| Week 12 | 82 (75 to 87) | 65 (41 to 85) | 75 (53 to 90) | 67 (45 to 84) | 100 (95 to 100) | 53 (29 to 76) |
| Week 16 | 87 (81 to 91) | 70 (46 to 88) | 71 (49 to 87) | 96 (79 to 100) | 100 (95 to 100) | 58 (33 to 80) |
| Week 24 | 88 (82 to 92) | 80 (56 to 94) | 79 (58 to 93) | 100 (86 to 100) | 100 (95 to 100) | 42 (20 to 67) |
| Week 28 | 87 (81 to 91) | 80 (56 to 94) | 79 (58 to 93) | 96 (79 to 100) | 99 (93 to 100) | 42 (20 to 67) |
| Week 36 | 83 (76 to 88) | 75 (51 to 91) | 75 (53 to 90) | 96 (79 to 100) | 95 (87 to 99) | 37 (16 to 62) |
| EOT | 87 (81 to 92) | 80 (56 to 94) | 79 (58 to 93) | 96 (79 to 100) | 99 (93 to 100) | 47 (24 to 71) |
HCV RNA levels were obtained routinely during and after treatment. Reductions in HCV RNA viral load by 1-log, 2-log, or 3-log increments were determined relative to Baseline HCV RNA. Each increment represents a reduction greater than or equal to (≥) the specified log value, including results for which HCV RNA was below the limit of quantification (25 IU/mL). The percentage of participants with each log reduction in HCV RNA was calculated as \[number of participants with log reduction divided by the number of participants analyzed\] multiplied by 100.
| percentage of participants | Total Population | Cirrhotics | Poor Responders | Late Responders | Early Responders | Others |
|---|---|---|---|---|---|---|
| 3-log, Week 2 | 12 (7 to 17) | 5 (0 to 25) | 0 (0 to 14) | 0 (0 to 14) | 19 (11 to 30) | 16 (3 to 40) |
| 3-log, Week 4 | 29 (22 to 37) | 20 (6 to 44) | 0 (0 to 14) | 8 (1 to 27) | 47 (36 to 59) | 26 (9 to 51) |
| 3-log, Week 6 | 88 (82 to 92) | 85 (62 to 97) | 75 (53 to 90) | 92 (73 to 99) | 97 (91 to 100) | 63 (38 to 84) |
| 3-log, Week 8 | 93 (88 to 97) | 95 (75 to 100) | 83 (63 to 95) | 100 (86 to 100) | 100 (95 to 100) | 68 (43 to 87) |
| 3-log, Week 12 | 95 (91 to 98) | 100 (83 to 100) | 88 (68 to 97) | 100 (86 to 100) | 100 (95 to 100) | 74 (49 to 91) |
| 3-log, Week 16 | 94 (89 to 97) | 95 (75 to 100) | 88 (68 to 97) | 100 (86 to 100) | 100 (95 to 100) | 68 (43 to 87) |
| 3-log, Week 24 | 90 (84 to 94) | 80 (56 to 94) | 83 (63 to 95) | 100 (86 to 100) | 100 (95 to 100) | 53 (29 to 76) |
| 3-log, Week 28 | 88 (83 to 93) | 80 (56 to 94) | 79 (58 to 93) | 96 (79 to 100) | 100 (95 to 100) | 53 (29 to 76) |
| 2-log, Week 2 | 27 (20 to 34) | 20 (6 to 44) | 0 (0 to 14) | 8 (1 to 27) | 42 (31 to 54) | 26 (9 to 51) |
| 2-log, Week 4 | 51 (43 to 59) | 50 (27 to 73) | 0 (0 to 14) | 33 (16 to 55) | 76 (65 to 85) | 37 (16 to 62) |
| 2-log, Week 6 | 95 (90 to 97) | 95 (75 to 100) | 96 (79 to 100) | 96 (79 to 100) | 99 (93 to 100) | 74 (49 to 91) |
| 2-log, Week 8 | 97 (93 to 99) | 100 (83 to 100) | 100 (86 to 100) | 100 (86 to 100) | 100 (95 to 100) | 74 (49 to 91) |
| 2-log, Week 12 | 95 (91 to 98) | 100 (83 to 100) | 88 (68 to 97) | 100 (86 to 100) | 100 (95 to 100) | 74 (49 to 91) |
| 2-log, Week 16 | 94 (89 to 97) | 95 (75 to 100) | 88 (68 to 97) | 100 (86 to 100) | 100 (95 to 100) | 68 (43 to 87) |
| 2-log, Week 24 | 90 (84 to 94) | 80 (56 to 94) | 83 (63 to 95) | 100 (86 to 100) | 100 (95 to 100) | 53 (29 to 76) |
| 2-log, Week 28 | 88 (83 to 93) | 80 (56 to 94) | 79 (58 to 93) | 96 (79 to 100) | 100 (95 to 100) | 53 (29 to 76) |
| 1-log, Week 2 | 55 (47 to 62) | 60 (36 to 81) | 0 (0 to 14) | 54 (33 to 74) | 73 (62 to 82) | 42 (20 to 67) |
| 1-log, Week 4 | 81 (74 to 86) | 75 (51 to 91) | 0 (0 to 14) | 100 (86 to 100) | 100 (95 to 100) | 84 (60 to 97) |
| 1-log, Week 6 | 98 (94 to 99) | 95 (75 to 100) | 100 (86 to 100) | 100 (86 to 100) | 100 (95 to 100) | 84 (60 to 97) |
| 1-log, Week 8 | 98 (95 to 100) | 100 (83 to 100) | 100 (86 to 100) | 100 (86 to 100) | 100 (95 to 100) | 84 (60 to 97) |
| 1-log, Week 12 | 96 (92 to 99) | 100 (83 to 100) | 96 (79 to 100) | 100 (86 to 100) | 100 (95 to 100) | 74 (49 to 91) |
| 1-log, Week 16 | 94 (89 to 97) | 95 (75 to 100) | 88 (68 to 97) | 100 (86 to 100) | 100 (95 to 100) | 68 (43 to 87) |
| 1-log, Week 24 | 91 (85 to 95) | 80 (56 to 94) | 88 (68 to 97) | 100 (86 to 100) | 100 (95 to 100) | 58 (33 to 80) |
| 1-log, Week 28 | 88 (83 to 93) | 80 (56 to 94) | 79 (58 to 93) | 96 (79 to 100) | 100 (95 to 100) | 53 (29 to 76) |
Virological relapse was defined as a detectable post-treatment HCV RNA viral load following a previously undetectable EOT level (ie, virological response). The percentage of participants with virological relapse was calculated as \[number of participants meeting the above criteria divided by the number of participants analyzed\] multiplied by 100.
| percentage of participants | Total Population | Cirrhotics | Poor Responders | Late Responders | Early Responders | Others |
|---|---|---|---|---|---|---|
| Percentage of Participants With Virological Relapse Following EOT Response | 7 (3 to 12) | 13 (2 to 38) | 5 (0 to 26) | 9 (1 to 28) | 4 (1 to 11) | 25 (3 to 65) |
Virological breakthrough was defined as an HCV RNA viral load greater than (\>) 1000 IU/mL following a previously undetectable level at any time during treatment (ie, virological response). Participants who ultimately achieved an EOT response were not considered for virological breakthrough. The percentage of participants with virological breakthrough was calculated as \[number of participants meeting the above criteria divided by the number of participants analyzed\] multiplied by 100.
| percentage of participants | Total Population | Cirrhotics | Poor Responders | Late Responders | Early Responders | Others |
|---|---|---|---|---|---|---|
| Percentage of Participants With Virological Breakthrough Following On-Treatment Response | 3 (1 to 7) | 0 (0 to 20) | 0 (0 to 18) | 4 (0 to 21) | 0 (0 to 5) | 23 (5 to 54) |
Virological rebound was defined as an HCV RNA viral load \>1000 IU/mL and a ≥1-log increase from nadir following a decline in HCV RNA from Baseline at any time during treatment (ie, on-treatment decline). Participants who ultimately achieved an EOT response were not considered for virological rebound. The percentage of participants with virological rebound was calculated as \[number of participants meeting the above criteria divided by the number of participants analyzed\] multiplied by 100.
| percentage of participants | Total Population | Cirrhotics | Poor Responders | Late Responders | Early Responders | Others |
|---|---|---|---|---|---|---|
| Percentage of Participants With Virological Rebound Following On-Treatment Decline in HCV RNA | 6 (3 to 11) | 5 (0 to 25) | 17 (5 to 37) | 4 (0 to 21) | 0 (0 to 5) | 22 (6 to 48) |
Treatment was to be discontinued for participants who met prespecified criteria, termed the futility rule, after 12 or 24 weeks of treatment. Participants were discontinued from treatment for one of the following reasons: HCV RNA viral load ≥100 IU/mL (Week 12) or a detectable HCV RNA viral load (Week 24). HCV RNA viral load was measured using the Roche COBAS TaqMan 2.0 HCV Test, with a lower LOD of 10 to 15 IU/mL. The percentage of participants with treatment discontinued for each reason was calculated as \[number of participants meeting one of the above criteria divided by the number of participants analyzed\] multiplied by 100.
| percentage of participants | Total Population | Cirrhotics | Poor Responders | Late Responders | Early Responders | Others |
|---|---|---|---|---|---|---|
| Week 12 | 4 | 10 | 13 | 0 | 0 | 11 |
| Week 24 | 3 | 5 | 8 | 0 | 0 | 11 |
The duration of treatment with each study drug was determined as the time from treatment start until the last dose of PEG-IFN, RBV, or boceprevir. Median duration of treatment was determined using the actual duration of treatment among individual participants and expressed in weeks.
| weeks | Total Population | Cirrhotics | Poor Responders | Late Responders | Early Responders | Others |
|---|---|---|---|---|---|---|
| PEG-IFN (n=165,20,24,24,78,19) | 28.0 (1 to 49) | 48.0 (14 to 48) | 48.0 (13 to 49) | 48.0 (32 to 48) | 28.0 (24 to 32) | 26.0 (1 to 48) |
| RBV (n=165,20,24,24,78,19) | 28.0 (1 to 49) | 48.0 (13 to 48) | 48.0 (14 to 49) | 48.0 (30 to 49) | 28.0 (10 to 33) | 27.0 (1 to 48) |
| Boceprevir (n=164,20,24,24,78,18) | 24.0 (1 to 45) | 44.0 (8 to 44) | 44.0 (10 to 45) | 32.0 (2 to 33) | 24.0 (6 to 25) | 10.0 (1 to 44) |
Dose modifications for each study drug included any dose reduction, treatment interruption, or premature withdrawal. Adverse event (AE)-related reasons were documented, as well as reasons related to insufficient efficacy ('Poor efficacy') or other safety-related reasons ('Safety/other'). The percentage of participants with a dose modification documented for each reason was calculated as \[number of participants with dose modification divided by the number of participants analyzed\] multiplied by 100.
| percentage of participants | Total Population | Cirrhotics | Poor Responders | Late Responders | Early Responders | Others |
|---|---|---|---|---|---|---|
| PEG-IFN, Any reason (n=165,20,24,24,78,19) | 52 | 60 | 54 | 46 | 42 | 84 |
| PEG-IFN, Anemia (n=165,20,24,24,78,19) | 1 | 0 | 0 | 0 | 1 | 5 |
| PEG-IFN, Asthenia (n=165,20,24,24,78,19) | 1 | 0 | 4 | 4 | 0 | 0 |
| PEG-IFN, Nausea/vomiting (n=165,20,24,24,78,19) | 0.6 | 0 | 0 | 0 | 1 | 0 |
| PEG-IFN, Neutropenia (n=165,20,24,24,78,19) | 36 | 30 | 38 | 33 | 36 | 47 |
| PEG-IFN, Rash (n=165,20,24,24,78,19) | 0.6 | 5 | 0 | 0 | 0 | 0 |
| PEG-IFN, Thrombocytopenia (n=165,20,24,24,78,19) | 5 | 35 | 4 | 0 | 1 | 0 |
| PEG-IFN, Safety/other (n=165,20,24,24,78,19) | 4 | 10 | 4 | 13 | 0 | 0 |
| PEG-IFN, Poor efficacy (n=165,20,24,24,78,19) | 8 | 15 | 21 | 4 | 0 | 21 |
| PEG-IFN, Not specified (n=165,20,24,24,78,19) | 12 | 0 | 8 | 13 | 8 | 42 |
| RBV, Any reason (n=165,20,24,24,78,19) | 64 | 65 | 67 | 46 | 62 | 89 |
| RBV, Anemia (n=165,20,24,24,78,19) | 46 | 50 | 46 | 38 | 53 | 26 |
| RBV, Asthenia (n=165,20,24,24,78,19) | 0.6 | 0 | 0 | 0 | 1 | 0 |
| RBV, Nausea/vomiting (n=165,20,24,24,78,19) | 1 | 0 | 0 | 0 | 0 | 11 |
| RBV, Neutropenia (n=165,20,24,24,78,19) | 3 | 0 | 0 | 4 | 0 | 21 |
| RBV, Rash (n=165,20,24,24,78,19) | 1 | 5 | 0 | 0 | 0 | 5 |
| RBV, Safety/other (n=165,20,24,24,78,19) | 8 | 15 | 8 | 13 | 3 | 16 |
| RBV, Poor efficacy (n=165,20,24,24,78,19) | 8 | 15 | 21 | 4 | 0 | 21 |
| RBV, Not specified (n=165,20,24,24,78,19) | 11 | 0 | 8 | 8 | 8 | 42 |
| Boceprevir, Any reason (n=164,20,24,24,78,18) | 28 | 45 | 29 | 21 | 12 | 89 |
| Boceprevir, Anemia (n=164,20,24,24,78,18) | 2 | 10 | 0 | 4 | 0 | 0 |
| Boceprevir, Asthenia (n=164,20,24,24,78,18) | 0.6 | 0 | 0 | 0 | 1 | 0 |
| Boceprevir, Nausea/vomiting (n=164,20,24,24,78,18) | 1 | 0 | 0 | 0 | 0 | 11 |
| Boceprevir, Neutropenia (n=164,20,24,24,78,18) | 4 | 0 | 0 | 4 | 0 | 28 |
| Boceprevir, Rash (n=164,20,24,24,78,18) | 1 | 5 | 0 | 0 | 0 | 6 |
| Boceprevir, Safety/other (n=164,20,24,24,78,18) | 4 | 10 | 0 | 4 | 0 | 17 |
| Boceprevir, Poor efficacy (n=164,20,24,24,78,18) | 7 | 15 | 21 | 0 | 0 | 17 |
| Boceprevir, Not specified (n=164,20,24,24,78,18) | 12 | 10 | 8 | 8 | 10 | 28 |
The frequency of missed treatments was examined using the number of administrations received as a percentage of target administrations for each study drug. The maximum number of possible administrations was considered in terms of once-weekly injections with PEG-IFN and in terms of treatment days with RBV and boceprevir. The percentage of target administrations each participant received was separated into ranges of \<60%, 60 to \<80%, 80 to \<95%, and ≥95% for each study drug. The percentage of participants who received each range of target administrations was calculated as \[number of participants in each range divided by the number of participants analyzed\] multiplied by 100.
| percentage of participants | Total Population | Cirrhotics | Poor Responders | Late Responders | Early Responders |
|---|---|---|---|---|---|
| PEG-IFN, <60% | 8 | 25 | 25 | 0 | 0 |
| PEG-IFN, 60 to <80% | 0.7 | 0 | 0 | 4 | 0 |
| PEG-IFN, 80 to <95% | 5 | 5 | 0 | 17 | 4 |
| PEG-IFN, 95% or more | 86 | 70 | 75 | 79 | 96 |
| RBV, <60% | 9 | 25 | 25 | 4 | 1 |
| RBV, 60 to <80% | 0.7 | 0 | 0 | 4 | 0 |
| RBV, 80 to <95% | 5 | 10 | 0 | 8 | 4 |
| RBV, 95% or more | 86 | 65 | 75 | 83 | 95 |
| Boceprevir, <60% | 10 | 30 | 25 | 8 | 1 |
| Boceprevir, 60 to <80% | 0.7 | 5 | 0 | 0 | 0 |
| Boceprevir, 80 to <95% | 3 | 5 | 0 | 4 | 3 |
| Boceprevir, 95% or more | 86 | 60 | 75 | 88 | 96 |
Dose modifications for each study drug included any dose reduction, treatment interruption, or premature withdrawal. The percentage of participants with a safety-related dose modification (eg, modification due to adverse event or laboratory abnormality) of any study drug was calculated as \[number of participants with dose modification divided by the number of participants analyzed\] multiplied by 100.
| participants | Total Population |
|---|---|
| Number of Participants With a Safety-Related Dose Modification | 113 |
Dose modifications for each study drug included any dose reduction, treatment interruption, or premature withdrawal. Median time to safety-related dose modification (eg, modification due to adverse event or laboratory abnormality) of any study drug was estimated using Kaplan-Meier and expressed in weeks.
| weeks | Total Population |
|---|---|
| Time to Safety-Related Dose Modification | 12.1 (10.3 to 16.0) |
Use of concomitant hematopoietic stimulants (such as epoetin) during the 48-week treatment period and/or within 24 weeks of follow-up was documented. The percentage of participants using concomitant hematopoietic stimulants was calculated as \[number of participants reporting concomitant use divided by the number of participants analyzed\] multiplied by 100.
| percentage of participants | Total Population |
|---|---|
| Percentage of Participants Using Concomitant Hematopoietic Stimulants During Treatment and Follow-Up | 6 |
The prevalence of concomitant disease at any time from Screening through the end of follow-up was documented. The percentage of participants with a concomitant disease was calculated as \[number of participants reporting or diagnosed with concomitant disease divided by the number of participants analyzed\] multiplied by 100. Diseases documented for ≥5% of participants included hypertension, diabetes mellitus, hypothyroidism, and vitamin D deficiency as reported here.
| percentage of participants | Total Population |
|---|---|
| Any disease | 53 |
| Hypertension | 18 |
| Diabetes mellitus | 8 |
| Hypothyroidism | 6 |
| Vitamin D deficiency | 5 |
Use of concomitant prescription or nonprescription medications during the 48-week treatment period and/or within 24 weeks of follow-up was documented. The percentage of participants using concomitant medications was calculated as \[number of participants reporting concomitant use divided by the number of participants analyzed\] multiplied by 100. Medication classes reported by \>10% of participants included analgesics, nonsteroidal anti-inflammatory drugs (NSAIDs), antihistamines, corticosteroids, proton pump inhibitors, vitamins and minerals, and beta-adrenoceptor blocking agents as reported here.
| percentage of participants | Total Population |
|---|---|
| Any medication | 79 |
| Analgesics | 29 |
| NSAIDs | 22 |
| Antihistamines | 19 |
| Corticosteroids | 19 |
| Proton pump inhibitors | 17 |
| Vitamins and minerals | 12 |
| Beta-adrenoceptor blocking agents | 11 |
Collected over Up to 72 weeks (from Baseline until 24 weeks after EOT). Non-serious events are listed at a 5% frequency threshold.
| Group | Deaths | Serious | Other |
|---|---|---|---|
| Cirrhotics (Safety) | — | 7/21 (33.3%) | 21/21 (100%) |
| Noncirrhotics (Safety) | — | 8/144 (5.6%) | 135/144 (93.8%) |
| Event | Cirrhotics (Safety) | Noncirrhotics (Safety) |
|---|---|---|
| AnaemiaBlood and lymphatic system disorders | 2/21 | 2/144 |
| Hepatic failureHepatobiliary disorders | 2/21 | 0/144 |
| ThrombocytopeniaBlood and lymphatic system disorders | 1/21 | 0/144 |
| Hepatic neoplasmNeoplasms benign, malignant and unspecified (incl cysts and polyps) | 1/21 | 0/144 |
| Hepatocellular carcinomaNeoplasms benign, malignant and unspecified (incl cysts and polyps) | 1/21 | 0/144 |
| PsoriasisSkin and subcutaneous tissue disorders | 1/21 | 0/144 |
| GranulocytopeniaBlood and lymphatic system disorders | 0/21 | 1/144 |
| NeutropeniaBlood and lymphatic system disorders | 0/21 | 1/144 |
| FatigueGeneral disorders | 0/21 | 1/144 |
| OverdoseInjury, poisoning and procedural complications | 0/21 | 1/144 |
| Event | Cirrhotics (Safety) | Noncirrhotics (Safety) |
|---|---|---|
| AnaemiaBlood and lymphatic system disorders | 7/21 | 57/144 |
| AstheniaGeneral disorders | 7/21 | 40/144 |
| NeutropeniaBlood and lymphatic system disorders | 5/21 | 47/144 |
| DysgeusiaNervous system disorders | 6/21 | 45/144 |
| Influenza like illnessGeneral disorders | 6/21 | 34/144 |
| ThrombocytopeniaBlood and lymphatic system disorders | 6/21 | 13/144 |
| HeadacheNervous system disorders | 2/21 | 32/144 |
| FatigueGeneral disorders | 4/21 | 31/144 |
| CoughRespiratory, thoracic and mediastinal disorders | 3/21 | 31/144 |
| PruritusSkin and subcutaneous tissue disorders | 4/21 | 30/144 |
All-Treated Population: All enrolled participants who received at least one dose of study medication.
| Age, Continuous(years) | Total Population |
|---|---|
| Mean | 45.8 ± 12.53 |
| Gender(Participants) | Total Population |
|---|---|
| Female | 83 |
| Male | 82 |
The record gives a start of Aug 2012, a primary completion of Jun 2014 and a completion of Jun 2014. It does not say whether these dates are actual or estimated.
Results were first posted in Aug 2015, 1 year 2 months after primary completion.
How these figures are worked out, and which studies are left out of them.
This study is completed, as verified in Nov 2016. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Studies of the drug tested here: Peginterferon alfa-2a